704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer

• Qingfeng Zhu,
• Robert Anders,
• Damian Trujillo,
• Dirk G Brockstedt,
• Michael Chisamore,
• Juraj Adamik,
• Paul D Kassner,
• William Ho,
• Rakesh Kumar Goyal,
• Adam Grant,
• Shoji Ikeda,
• Marvin Au,
• Denise Nagata,
• Eugene Lurie,
• Mohsen Sabouri Ghomi

Affiliations

Qingfeng Zhu

3Johns Hopkins University School of Medicine, Baltimore, MD, USA

Robert Anders

7Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA

Damian Trujillo

Aff16 grid.417411.6Aduro Biotech Inc Berkeley CA USA

Dirk G Brockstedt

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Michael Chisamore

10Merck and Co., Inc., Rahway, NJ, USA

Juraj Adamik

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Paul D Kassner

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

William Ho

11RAPT Therapeutics, Inc., South San Francisco, CA, USA

Rakesh Kumar Goyal

12RAPT Therapeutics, Redwood City, CA, USA

Adam Grant

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Shoji Ikeda

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Marvin Au

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Denise Nagata

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Eugene Lurie

1RAPT Therapeutics, Inc., South San Francisco, CA, USA

Mohsen Sabouri Ghomi

1RAPT Therapeutics, Inc., South San Francisco, CA, USA